CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

CRISPR Therapeutics (CRSP) has declined 23.6% in the year-to-date period compared with the industry's 1.7% fall, as seen in the chart below. The stock also underperformed the sector and the S&P 500. The shares are also trading below its 50-day and 200-day moving averages. Zacks Investment Research Image Source: CRSP Stock Underperforms Industry, Sector & S&P 500 Since the start of this year, CRSP received approval for its Vertex Pharmaceuticals (VRTX) -partnered oneshot gene therapy Casgevy in two blood dis ...